Remedium Bio has announced the initial closing of a planned $10 million Series A financing to advance its durable protein therapeutics platform toward first-in-human development. The financing is being led by Lifespan Vision Ventures, with participation from Eli Lilly and Company and HKX Capital, strengthening the Boston-based biotechnology company’s investor base as it moves its technology closer to clinical testing. As part of the transaction, Harry Robb of Lifespan Vision Ventures has joined Remedium Bio’s board of directors.
Series A Supports Clinical Development
Remedium said proceeds from the financing will be directed toward advancing its lead programs, expanding its proprietary platform technologies, and preparing for first-in-human clinical studies. The company expects the Series A to help it reach several development milestones while generating additional evidence for the potential use of its technology across cardiometabolic and other chronic diseases. Chief Executive Officer and co-founder Frank Luppino said the initial close reflects investor confidence in Remedium’s scientific progress and its approach to changing how chronic protein therapies are delivered.
A Different Approach to Protein Therapeutics
Remedium is developing platforms designed to enable durable and controlled production of therapeutic proteins following a minimally invasive subcutaneous administration. Its technology uses adipocytes, or fat cells, as a long-term site for therapeutic protein production, with the aim of providing multi-year therapeutic effects while retaining the ability to adjust expression levels according to individual dosing requirements. The company believes this model could address several limitations associated with frequently administered biologic medicines, including the burden of repeat injections and fluctuations in drug exposure between doses.
Building Around the Prometheus Platform
At the center of Remedium’s technology strategy is Prometheus, its proprietary adjustable gene therapy platform, which is intended to replace certain repeatedly injected protein therapies with a single administration capable of sustained therapeutic gene expression. Remedium has been developing the platform across several therapeutic areas, including endocrinology, immunology, neurology, and musculoskeletal diseases, while focusing particular attention on conditions requiring chronic treatment. In March 2026, the company reported peer-reviewed preclinical work involving a lipid nanoparticle-based DNA delivery system that produced prolonged expression of therapeutic peptides and improved metabolic measures in animal models of obesity and type 2 diabetes.
Relationship With Eli Lilly Expands
Lilly’s participation in the Series A follows an existing relationship between the pharmaceutical company and Remedium Bio. In September 2025, the companies announced a multi-target research and development collaboration focused on using Prometheus to develop gene therapies for obesity and type 2 diabetes, with Remedium eligible for an upfront payment, equity investment, milestone payments, and royalties under the agreement. Remedium also established research operations at Lilly Gateway Labs in Boston in 2025, providing the biotechnology company with access to infrastructure and drug-development resources as it expanded its platform and pipeline.
The initial Series A close gives Remedium additional capital to transition its durable protein therapeutics technology from preclinical development toward human studies while continuing to broaden its pipeline. The participation of Lifespan Vision Ventures, Lilly, and HKX Capital also adds financial and strategic backing at a stage when the company is preparing to demonstrate whether its adjustable, long-duration approach can translate into clinically viable treatments. Remedium plans to complete the $10 million round with additional investors as it works toward its next development milestones and the first clinical evaluation of its technology.